Tradestie Institutional Equity Comparison Engine

MYGN vs IMDX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MYGN Overall Edge

MYGN Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Myriad Genetics Inc (MYGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MYGN trades at 54.0x Forward P/E with -13.3% operating margin (-1.5% YoY revenue) versus IMDX at N/M Forward P/E and -1883.2% operating margin (+115.0% YoY). In options structure, MYGN sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro) against IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MYGN
MYGN 54.0x vs IMDX N/M Fwd P/E
Growth & Margin Winner MYGN
Op Margin -13.3% vs -1883.2% ยท YoY -1.5% vs +115.0%
Momentum & Technical Winner MYGN
1Y -16.4% vs -73.8% ยท 52W Pos 52% vs 3%
Options & Structure Winner MYGN
CONSOLIDATION (22nd %ile IV) vs BREAKDOWN (12th %ile IV)
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.54
+0.18% 1D
Market Cap $530.4M
1M Return -0.54%
1Y Return -16.44%
Forward P/E 54.0x
Unified AI Score
45.4 / 100 HOLD
Tech 42.0 Fund 48.0 Flow 59.0 Mom 50.0
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
1M Return -45.03%
1Y Return -73.78%
Forward P/E N/M
Unified AI Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MYGN -16.44% IMDX -73.78% Spread: +57.34 pp (MYGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MYGN Revenue IMDX Revenue MYGN Op. Margin IMDX Op. Margin Margin Edge
FY2018 $740M N/A 16.4% N/A MYGN
FY2019 $850M N/A 0.9% N/A MYGN
FY2020 $560M $0M -52.0% -2443.3% MYGN
FY2021 $690M $0M -27.6% -2444.3% MYGN
FY2022 $680M $0M -20.7% -1878.6% MYGN
FY2023 $750M $0M -34.2% -1672.4% MYGN
FY2024 $840M $0M -14.7% -3245.1% MYGN
FY2025 $820M $0M -47.0% -1260.8% MYGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MYGN (7) vs IMDX (2)
Institutional Metric MYGN IMDX Criterion Row Winner
Market Capitalization Scale $530.4M $52.1M Larger Scale MYGN
Trailing P/E Ratio Valuation 54.0x N/M Lower Multiple MYGN
Forward P/E Ratio Valuation 54.0x N/M Lower Multiple MYGN
Revenue Growth (YoY) Growth -1.5% +115.0% Higher Growth IMDX
Operating Margin (TTM) Profitability -13.3% -1883.2% Higher Margin MYGN
Net Profit Margin Profitability -16.1% 0.0% Higher Margin IMDX
Return on Equity (ROE) Capital Efficiency -40.2% -23603.1% Higher ROE MYGN
52-Week Range Position Momentum 52% ($3โ€“$8) 3% ($2โ€“$8) Stronger Trend MYGN
Beta / 30D Volatility Risk Regime 0.63ฮฒ ยท 54% Vol 2.91ฮฒ ยท 76% Vol Lower Realized Risk MYGN
Unified Institutional Score Composite Signal 45.4 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite Tie

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MYGN vs IMDX Buy Guide
MYGN CONSOLIDATION
15d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live MYGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IMDX BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live IMDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MYGN nor IMDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.